G P Stathopoulos

Summary

Affiliation: University of Athens
Country: Greece

Publications

  1. ncbi request reprint Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study
    Athanasios Athanasiadis
    Oncology Department, General Hospital of Larissa, Tsakalof 1, 41 221, Larissa, Greece
    Cancer Chemother Pharmacol 56:653-8. 2005
  2. ncbi request reprint Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer
    Marinos Veslemes
    University Clinic, Sotiria Hospital, Athens, Greece
    Anticancer Res 25:2991-6. 2005
  3. ncbi request reprint Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer
    Dimosthenis Antoniou
    7th Department of Pulmonary Medicine, Sotiria Hospital of Chest Diseases, Athens, Greece
    Lung Cancer 53:205-10. 2006
  4. pmc Lipoplatin formulation review article
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    J Drug Deliv 2012:581363. 2012
  5. ncbi request reprint Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    J BUON 17:735-9. 2012
  6. pmc Combination of three cytotoxic agents in small-cell lung cancer
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Semitelou 2A, 115 28, Athens, Greece
    Cancer Chemother Pharmacol 71:413-8. 2013
  7. ncbi request reprint Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
    G P Stathopoulos
    First Department of Medical Oncology, Errikos Dynan Hospital of Athens, Athens, Greece
    Ann Oncol 14:388-94. 2003
  8. ncbi request reprint Mesothelioma: treatment and survival of a patient population and review of the literature
    John Stathopoulos
    SOLCA Study Group and First Department of Medical Oncology, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 25:3671-6. 2005
  9. ncbi request reprint Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 27:1653-6. 2007
  10. ncbi request reprint Therapeutic administration of pegfilgrastim instead of prophylactic use
    George P Stathopoulos
    First Oncology Department, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 25:2445-8. 2005

Collaborators

Detail Information

Publications70

  1. ncbi request reprint Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study
    Athanasios Athanasiadis
    Oncology Department, General Hospital of Larissa, Tsakalof 1, 41 221, Larissa, Greece
    Cancer Chemother Pharmacol 56:653-8. 2005
    ....
  2. ncbi request reprint Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer
    Marinos Veslemes
    University Clinic, Sotiria Hospital, Athens, Greece
    Anticancer Res 25:2991-6. 2005
    ..The second cytotoxic drug administered was either etoposide or gemcitabine. First-line treatment was based on paclitaxel combined with either carboplatin or vinorelbine...
  3. ncbi request reprint Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer
    Dimosthenis Antoniou
    7th Department of Pulmonary Medicine, Sotiria Hospital of Chest Diseases, Athens, Greece
    Lung Cancer 53:205-10. 2006
    ..All of the above values were statistically significant. D-Dimer plasma levels decrease or increase after response and progressive disease, respectively, and can act as a predictive factor of the evolution of the disease...
  4. pmc Lipoplatin formulation review article
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    J Drug Deliv 2012:581363. 2012
    ....
  5. ncbi request reprint Maintenance chemotherapy or not in ovarian cancer stages IIIA, B, C, and IV after disease recurrence
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    J BUON 17:735-9. 2012
    ..In the present trial we compared the median survival of patients with residual or recurrent disease who received 1-2 lines of chemotherapy with those who received 3-9 lines...
  6. pmc Combination of three cytotoxic agents in small-cell lung cancer
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Semitelou 2A, 115 28, Athens, Greece
    Cancer Chemother Pharmacol 71:413-8. 2013
    ..Our objectives were to determine an equal or longer survival and lower toxicity by administering all 3 drugs with low dosage on day one, compared to the established guideline of 3-day administration...
  7. ncbi request reprint Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: a multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer
    G P Stathopoulos
    First Department of Medical Oncology, Errikos Dynan Hospital of Athens, Athens, Greece
    Ann Oncol 14:388-94. 2003
    ..The efficacy and toxicity of gemcitabine (GEM) and irinotecan (CPT-11) is evaluated in previously untreated patients with inoperable or metastatic pancreatic cancer...
  8. ncbi request reprint Mesothelioma: treatment and survival of a patient population and review of the literature
    John Stathopoulos
    SOLCA Study Group and First Department of Medical Oncology, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 25:3671-6. 2005
    ..A review of the literature with respect to these parameters is included...
  9. ncbi request reprint Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 27:1653-6. 2007
    ..The aim of the present study was to estimate the efficacy of this agent in pretreated patients with advanced breast and colorectal cancer, and to determine the response rate and adverse reactions...
  10. ncbi request reprint Therapeutic administration of pegfilgrastim instead of prophylactic use
    George P Stathopoulos
    First Oncology Department, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 25:2445-8. 2005
    ....
  11. ncbi request reprint Present treatment and future expectations in advanced pancreatic cancer
    George P Stathopoulos
    First Department of Oncology, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 28:1303-8. 2008
    ..Trials of these and other targeting therapies have not produced the expected effectiveness. The combination of monoclonal and/or gene therapies with cytotoxic agents suggests there is hope for the future...
  12. ncbi request reprint Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study
    G P Stathopoulos
    First Oncology Department, Errikos Dunant Hospital, Semitelou 2A, Athens, Greece
    Cancer Chemother Pharmacol 56:487-91. 2005
    ..This is a phase II study where a novel chemotherapy combination was tested in pre-treated breast cancer patients: docetaxel and irinotecan have already been established as agents for breast and colorectal cancer, respectively...
  13. ncbi request reprint Survival after cytotoxic chemotherapy in patients with advanced hormone-resistant prostate cancer: a phase II study
    George P Stathopoulos
    First Oncology Department, Errikos Dunant Hospital, 115 28 Athens, Greece
    Oncol Rep 22:345-8. 2009
    ..66%, respectively. Toxicity was well-tolerated. Patients with hormone-resistant advanced prostate cancer do have good prospects for receiving substantial benefit with the addition of chemotherapy, as observed in the present trial...
  14. ncbi request reprint Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study
    G P Stathopoulos
    First Department of Oncology, Errikos Dunant Hospital, Semitelou 2A, 115 28 Athens, Greece
    Cancer Chemother Pharmacol 57:796-800. 2006
    ....
  15. pmc Front-line paclitaxel and irinotecan combination chemotherapy in advanced non-small-cell lung cancer: a phase I-II trial
    G P Stathopoulos
    First Oncology Deptartment, Errikos Dunant Hospital, Athens, Greece
    Br J Cancer 93:1106-11. 2005
    ..2%) patients and diarrhoea (grade 3) in four (7.7%) patients. Irinotecan combined with paclitaxel, administered every 2 weeks, appears to be an effective treatment for advanced-stage NSCLC...
  16. ncbi request reprint Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin
    George P Stathopoulos
    First Oncology Dept, Errikos Dunant Hospital, Athens, Greece
    Am J Clin Oncol 28:565-9. 2005
    ..We planned this phase 2 study in patients pretreated with IFL, adding oxaliplatin as second-line treatment: our objectives were to determine response rate and overall survival...
  17. ncbi request reprint Front-line paclitaxel and topotecan chemotherapy in advanced or metastatic non-small-cell lung cancer: a phase II trial
    G P Stathopoulos
    First Oncology Department, Errikos Dunant Hospital, Athens, Greece
    Cancer Chemother Pharmacol 58:555-60. 2006
    ..Our primary objective was to determine the response rate and survival and our secondary objective, the safety of the regimen...
  18. ncbi request reprint Liposomal cisplatin combined with gemcitabine in pretreated advanced pancreatic cancer patients: a phase I-II study
    George P Stathopoulos
    Errikos Dunant Hospital and Medical School of Athens, Greece
    Oncol Rep 15:1201-4. 2006
    ..3%). Liposomal cisplatin is a non-toxic alternative agent to bare cisplatin. In combination with gemcitabine, it has an MTD of 100 mg/m2 and shows promising efficacy in refractory pancreatic cancer...
  19. ncbi request reprint Metastatic renal cancer and patient survival as a criterion of treatment response
    George P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Semitelou 2A, 115 28 Athens, Greece
    Oncol Rep 19:477-81. 2008
    ..In the latter studies, despite the high response rates (31-40%), the survival was 16.4 months. Our data indicate that the response rate as a criterion is not adequate in determining drug effectiveness...
  20. ncbi request reprint Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial
    George P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    Lung Cancer 57:66-71. 2007
    ..The combination of pemetrexed and paclitaxel at doses of 500mg/m(2) and 175mg/m(2), respectively, has been shown to be an effective combination with very limited toxicity...
  21. pmc A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer
    G P Stathopoulos
    Hellenic Oncology Research Group HORG and Hellenic Cooperative Oncology Group HeCOG, Semitelou 2A, 115 28 Athens, Greece
    Br J Cancer 95:587-92. 2006
    ..8% for the G arm. No statistically significant difference was observed comparing gemcitabine monotherapy versus gemcitabine plus irinotecan in the treatment of advanced pancreatic cancer, with respect to overall and 1-year survival...
  22. ncbi request reprint Differences in gene expression between individuals with multiple primary and single primary malignancies
    G P Stathopoulos
    A Oncology Department, Errikos Dunant Hospital, 11528 Athens, Greece
    Int J Mol Med 24:613-22. 2009
    ..Nine of those were confirmed by the classifier analysis...
  23. ncbi request reprint Governmental strategies for cancer control, prevention, care and management in Greece
    G P Stathopoulos
    Errikos Dunant Hospital, Athens, Greece
    J BUON 14:533-6. 2009
    ..The targets are the collection of reliable information, primary and secondary prevention, effective treatment and a better quality of life for the patient...
  24. ncbi request reprint Long-term survival of patients with advanced colorectal cancer may not be due to the response to chemotherapy
    George P Stathopoulos
    Hippokration General Hospital, University Clinic, Oncology Department, Athens, Greece
    Oncol Rep 12:1295-300. 2004
    ..Median survival of patients with stable disease was 19 months and of untreated patients 12 months. Patients with advanced colorectal cancer have a long median (25 months) and overall survival, despite low responsiveness to chemotherapy...
  25. doi request reprint Granulocyte colony-stimulating factor expression as a prognostic biomarker in non-small cell lung cancer
    G P Stathopoulos
    Semitelou 2A, 11528 Athens, Greece
    Oncol Rep 25:1541-4. 2011
    ..We assume that these findings may indicate that increased G-CSF levels may function as a biomarker of survival...
  26. doi request reprint Treatment of colorectal cancer with and without bevacizumab: a phase III study
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    Oncology 78:376-81. 2010
    ..The objective of this phase III trial was to compare chemotherapy combined with bevacizumab versus chemotherapy alone in the treatment of patients with advanced colorectal cancer...
  27. doi request reprint Liposomal cisplatin: a new cisplatin formulation
    George P Stathopoulos
    Department of First Oncology, Errikos Dunant Hospital, Athens, Greece
    Anticancer Drugs 21:732-6. 2010
    ..This review aims to chronologically document publications relevant to liposomal cisplatin to date...
  28. ncbi request reprint Liposomal cisplatin dose escalation for determining the maximum tolerated dose and dose-limiting toxicity: a phase I study
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 30:1317-21. 2010
    ....
  29. ncbi request reprint Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study
    George P Stathopoulos
    First Oncology Department Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 26:1489-93. 2006
    ..Our objectives were to determine the adverse reactions, dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of lipoxal...
  30. ncbi request reprint Paclitaxel and vinorelbine combination in advanced inoperable adenocarcinoma of the lung: a phase II study
    George P Stathopoulos
    First Department of Medical Oncology, Errikos Dynan Hospital, Athens, Greece
    Anticancer Res 23:3479-84. 2003
    ..The purpose of this study was to determine the efficacy of paclitaxel (PCT) combined with vinorelbine (VRL) in adenocarcinoma of the lung...
  31. pmc Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    Ann Oncol 21:2227-32. 2010
    ....
  32. ncbi request reprint Serious hematologic complications following erlotinib treatment
    G P Stathopoulos
    Semitelou 2A, 115 28 Athens, Greece
    Anticancer Res 30:973-6. 2010
    ..Erlotinib is an oral, small-molecule targeting therapy which inhibits epidermal growth factor tyrosine kinase receptors. Erlotinib has been administered for the treatment of advanced pancreatic cancer and non-small cell lung cancer...
  33. ncbi request reprint Long-term survival of patients with carcinoid tumor and liver metastases
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    J BUON 14:609-11. 2009
    ..To determine long-term survival and long-term stable disease in patients with atypical carcinoid tumor with liver metastases...
  34. ncbi request reprint Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial
    G P Stathopoulos
    First Department of Medical Oncology, Errikos Dynan Hospital, Athens
    Ann Oncol 15:1048-55. 2004
    ....
  35. pmc Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Semitelou 2A, 115 28, Athens, Greece
    Cancer Chemother Pharmacol 68:945-50. 2011
    ..Our objective was to compare the effectiveness of lipoplatin combined with paclitaxel versus cisplatin with paclitaxel in advanced non-squamous NSCLC...
  36. ncbi request reprint Weekly administration of topotecan-paclitaxel as second-line treatment in ovarian cancer
    G P Stathopoulos
    First Department of Oncology, Errikos Dunant Hospital, Semitelou 2A, 115 28, Athens, Greece
    Cancer Chemother Pharmacol 60:123-8. 2007
    ..To investigate the weekly administration of topotecan combined with paclitaxel in pretreated advanced ovarian cancer patients; our objectives were to determine efficacy, toxicity and survival...
  37. ncbi request reprint Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study
    George P Stathopoulos
    First and Second Departments of Medical Oncology, Errikos Dunant Hospital, Semitelou 5, 115 28 Athens, Greece
    Cancer Chemother Pharmacol 54:259-64. 2004
    ....
  38. ncbi request reprint Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study
    G P Stathopoulos
    Hellenic Oncology Research Group, Athens, Greece
    Ann Oncol 15:224-9. 2004
    ..To evaluate the efficacy and toxicity of gemcitabine (GEM) combined with capecitabine (CAP) in untreated patients with inoperable or metastatic pancreatic cancer...
  39. doi request reprint Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study
    George P Stathopoulos
    Department of First Oncology, Errikos Dunant Hospital, Semitelou 2A, Athens 115 28, Greece
    Anticancer Drugs 21:202-5. 2010
    ..3 mg/m(2) for 4 days without prophylactic granulocyte colony-stimulating factor administration. The safe duration of oral topotecan treatment and the maximum tolerated dose seem to be not longer than 3 days at a dose of 2.3 mg/m(2)...
  40. ncbi request reprint Alternate paclitaxel-gemcitabine and paclitaxel-vinorelbine biweekly administration in non-small cell lung cancer patients: a phase II study
    J Dimitroulis
    Sixth Clinic, Sotiria Hospital of Chest Diseases, Athens, Greece
    Anticancer Res 26:1397-402. 2006
    ..All 3 drugs have been used in other 2-agent combinations and have been shown to be effective as first-line therapy...
  41. ncbi request reprint Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study
    G Aravantinos
    Agii Anargiri Cancer Hospital, Athens, Greece
    Ann Oncol 16:1116-22. 2005
    ..The two platinum derivatives have been previously combined as they are not totally cross-resistant and as they share no overlapping toxicities...
  42. ncbi request reprint Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)
    Jim Janinis
    Social Security Organization Oncology Center, Athens, Greece
    Anticancer Drugs 15:479-87. 2004
    ..The combination of paclitaxel with PLD demonstrated activity in recurrent or metastatic HNC, a favorable toxicity profile and relative ease of administration...
  43. ncbi request reprint Surgical management in lung metastases from colorectal cancer
    J Dahabre
    Thoracic Surgery Clinic, latriko Center of Athens, Athens, Greece
    Anticancer Res 27:4387-90. 2007
    ..The aim of the present study was to show the evolution of patients with lung metastases from colorectal cancer, treated with surgery...
  44. ncbi request reprint Angiosarcoma of the heart: case report and review of the literature
    S Batzios
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 26:4837-42. 2006
    ..Primary angiosarcoma of the heart is an extremely rare malignant disease...
  45. ncbi request reprint Primitive neurectodermal tumors: a case of extraosseous Ewing's sarcoma of the small intestine and review of the literature
    C Batziou
    First Department of Oncology, Errikos Dunant Hospital, Athens, Greece
    J BUON 11:519-22. 2006
    ..ES of the small intestine, described here, has not been previously documented in the literature. Along with the other different documented sites, a new location of primary extraosseous ES is also reported here...
  46. ncbi request reprint Multiple lines of chemotherapy in relation to survival of patients on recurrence with advanced ovarian cancer
    G P Stathopoulos
    Errikos Dunant, Athens, Greece Marika Iliadi Hospital, Athens, Greece Agii Anargyri Hospital, Athens, Greece Errikos Dunant Hospital, Athens, Greece
    J Clin Oncol 26:16553. 2008
    ..Patients after recurrence survive for an unpredictable period of time, often of very long duration. In the present study the objectives were: response and patients survival in relation to the number of chemotherapy treatments...
  47. ncbi request reprint Metastatic lung disease treated with pemetrexed-docetaxel combination chemotherapy
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    J BUON 16:166-9. 2011
    ..Herein we present the preliminary data of a trial whose objective was to investigate the effectiveness to 2 combined agents in patients with heavily pretreated adenocarcinomas...
  48. ncbi request reprint p53, p21 and p27 protein expression in head and neck cancer and their prognostic value
    N Kapranos
    Department of Pathology, Division of Molecular Pathology, Amalia Fleming Hospital, Athens, Greece
    Anticancer Res 21:521-8. 2001
    ....
  49. ncbi request reprint Lung carcinoid tumor biology: treatment and survival
    J Dahabreh
    Thoracic Surgery Clinic, Iatriko Center, Athens, Athens, Greece
    Oncol Rep 21:757-60. 2009
    ..The patients with liver metastases who underwent no specific treatment had a median survival as long as 8 years...
  50. ncbi request reprint Pharmacokinetics and adverse reactions of a new liposomal cisplatin (Lipoplatin): phase I study
    George P Stathopoulos
    Errikos Dunant Hospital and Medical School of Athens, Athens, Greece
    Oncol Rep 13:589-95. 2005
    ..Urine excretion reached about 40% of the infused dose in 3 days. The data demonstrate that Lipoplatin up to a dose of 125 mg/m2 every 14 days has no nephrotoxicity and it lacks the serious side effects of cisplatin...
  51. ncbi request reprint Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study
    John Dimitroulis
    Hospital of Thoracic Diseases, Athens, Greece
    Oncol Rep 20:879-84. 2008
    ..The former combination could be applied as an alternative chemotherapy regimen for patients with limited or advanced small-cell lung cancer...
  52. ncbi request reprint Response to radiotherapy in brain metastases and survival of patients with non-small cell lung cancer
    Dimosthenis Antoniou
    Hospital of Thoracic Diseases, Athens, Greece
    Oncol Rep 14:733-6. 2005
    ..9-6.1]. Responders had statistically significant longer survival than non-responders. Although responders represented less than half of our patients with NSCLC and brain metastases, they had significantly longer survival...
  53. ncbi request reprint High-dose tamoxifen in breast cancer bone metastasis
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    J BUON 18:532-4. 2013
    ..All of them had been pretreated with hormonal therapy, including lowdose tamoxifen. The results were extremely positive with clinical amelioration and also disappearance of osteolysis in 5 patients. ..
  54. ncbi request reprint Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer
    A Giatromanolaki
    Tumour and Angiogenesis Research Group, Iraklion, Crete, Greece
    Oncol Res 12:33-41. 2000
    ..Such a categorization may be useful for phase III trials on novel therapies targeting the major angiogenesis-related features studied here...
  55. ncbi request reprint Phase II trial of biweekly administration of vinorelbine and gemcitabine in pretreated advanced breast cancer
    George P Stathopoulos
    Department of Oncology, Second Division of Medicine, Hippokration Hospital, University of Athens, Athens, Greece
    J Clin Oncol 20:37-41. 2002
    ..To determine the efficacy of gemcitabine (GEM) plus vinorelbine (VRL) administered biweekly in pretreated patients with advanced breast cancer...
  56. ncbi request reprint Hormone refractory advanced prostate cancer treated with estramustine and paclitaxel combination
    Athanasios Athanasiadis
    Oncology Department, General Hospital of Larissa, Greece
    Anticancer Res 23:3085-8. 2003
    ..The objective of the present study was to investigate the effectiveness of weekly paclitaxel administration in combination with oral estramustine in patients with prostate cancer refractory to hormonal manipulation...
  57. ncbi request reprint Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study
    Sotiris K Rigatos
    Oncology Department, Errikos Dynan Hospital, Athens, Greece
    Oncol Rep 10:1817-9. 2003
    ..The high hand-foot adverse reaction (47.83%) inhibited the continuation of treatment in half of the patients and due to this toxicity the trial was terminated after the 23rd patient...
  58. ncbi request reprint A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens
    Christos Kosmas
    Second Division of Medical Oncology, Department of Medicine, Metaxa Cancer Hospital, Piraues, 21 Apolloniou Street, 16341, Athens, Greece
    Cancer Chemother Pharmacol 59:51-9. 2007
    ..In the present phase I-II study, we evaluated the feasibility and efficacy of bi-weekly gemcitabine (GEM) + irinotecan (CPT-11) in patients with relapsed NSCLC...
  59. ncbi request reprint Evolution of non-small cell lung cancer chemotherapy (Review)
    John Dimitroulis
    Sotiria Hospital, 6th Clinic, Errikos Dunant Hospital, Athens, Greece
    Oncol Rep 13:923-30. 2005
    ..the newer ones. It seems that combinations with or without cisplatin are of similar effectiveness with respect to response rate and median and overall survival but the toxicity is different with a prevalence of myelotoxicity...
  60. ncbi request reprint Cisplatin: process and future
    G P Stathopoulos
    First Oncology Clinic, Errikos Dunant Hospital, Athens, Greece
    J BUON 18:564-9. 2013
    ..Recently, a novel formulation of CDDP, liposomal cisplatin, which has shown very low toxicity, no nephrotoxicity and equal effectiveness was produced; its importance is its higher effectiveness than standard CDDP in lung adenocarcinoma. ..
  61. ncbi request reprint Co-expression of trypsin and tumour-associated trypsin inhibitor (TATI) in colorectal adenocarcinomas
    S Solakidi
    Institute of Biological Research, National Hellenic Research Foundation, Athens, Greece
    Histol Histopathol 18:1181-8. 2003
    ..We conclude that in colorectal neoplasms, high levels of trypsin and TATI may be important for malignant tumour formation and/or metastatic process...
  62. pmc Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors
    C N Baxevanis
    Department of Immunology, Hellenic Anticancer Institute, Athens, Greece
    Br J Cancer 70:625-30. 1994
    ..Selective enrichment in T-cell subsets by IL-1 beta may be useful in cellular adoptive immunotherapy using cells isolated from malignant effusions...
  63. ncbi request reprint Influence of 5-fluorouracil on serum lipids
    G P Stathopoulos
    Department of Oncology, Hippokration Hospital, Athens, Greece
    Acta Oncol 34:253-6. 1995
    ..Maximal cholesterol-lowering effect was observed in patients and rabbits with higher baseline cholesterol levels. The results suggest that 5-FU might interfere with lipid metabolism...
  64. ncbi request reprint Decreased plasma ghrelin levels in patients with advanced cancer and weight loss in comparison to healthy individuals
    Ioannis Legakis
    Department of Endocrinology and Metabolism, Errikos Dunant Hospital, Athens, Greece
    Anticancer Res 29:3949-52. 2009
    ..The aim of the present study was to investigate the plasma ghrelin levels in cancer patients with a low performance status and weight loss and compare them with those of healthy individuals without weight loss...
  65. ncbi request reprint A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer
    Michail Ignatiadis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Oncology 71:159-63. 2006
    ..To evaluate the efficacy and tolerance of the docetaxel/gefitinib combination as second-line treatment in patients with advanced pancreatic cancer...
  66. ncbi request reprint The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study
    George Koutinos
    Hippokration Hospital, 2nd Medical Division, University of Athens School of Medicine, Greece
    Anticancer Res 22:815-20. 2002
    ..In vitro testing of oxygen-free radical production showed high production by doxorubicin and very low production by mitoxantrone. Thus, mitoxantrone appears to be safer than doxorubicin...
  67. ncbi request reprint Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study
    Nikolaos Androulakis
    Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
    Cancer Invest 23:9-12. 2005
    ..LOHP merits further investigation in combination with other drugs as palliative treatment of pretreated patients with advanced pancreatic cancer...
  68. ncbi request reprint BRCA2 gene mutations in Greek patients with familial breast cancer
    Athanasios Armakolas
    Laboratory of Surgical Research, A Propaedeutic Surgical Clinic, Athens Medical School, Hippokrateion Hospital, Athens, Greece
    Hum Mutat 19:81-2. 2002
    ..Our findings suggest that there is a cluster of novel mutations in exons 10 and 11 in Greek patients with familial breast cancer. These mutations appear to have a milder clinical phenotype when compared to the rest of the study group...
  69. ncbi request reprint Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies
    Sylvia Solakidi
    Institute of Biological Research, National Hellenic Research Foundation, 116 35 Athens, Greece
    Clin Biochem 37:56-60. 2004
    ..Elevated serum tumour-associated trypsin inhibitor (TATI) levels have been observed in association with malignancy or inflammation. The aim of our study was to evaluate the role of TATI in gastric and colorectal cancer...
  70. ncbi request reprint Investigation of doxorubicin tissue toxicity: does amifostine provide chemoprotection? An experimental study
    Sotiris K Rigatos
    Hippokration Hospital, 2nd Medical Division, University of Athens School of Medicine, Greece
    Anticancer Res 22:129-34. 2002
    ..In in vitro testing, Amifostine was found to be a scavenger of the oxygen-free radicals which are produced by Doxorubicin...